Spero Therapeutics (SPRO) Competitors $0.83 -0.01 (-0.68%) Closing price 02/21/2025 04:00 PM EasternExtended Trading$0.80 -0.03 (-3.37%) As of 02/21/2025 04:09 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends SPRO vs. HURA, ZNTL, NLTX, CRGX, VXRT, ACRV, CDTX, ALEC, ACRS, and IKTShould you be buying Spero Therapeutics stock or one of its competitors? The main competitors of Spero Therapeutics include TuHURA Biosciences (HURA), Zentalis Pharmaceuticals (ZNTL), Neoleukin Therapeutics (NLTX), CARGO Therapeutics (CRGX), Vaxart (VXRT), Acrivon Therapeutics (ACRV), Cidara Therapeutics (CDTX), Alector (ALEC), Aclaris Therapeutics (ACRS), and Inhibikase Therapeutics (IKT). These companies are all part of the "pharmaceutical products" industry. Spero Therapeutics vs. TuHURA Biosciences Zentalis Pharmaceuticals Neoleukin Therapeutics CARGO Therapeutics Vaxart Acrivon Therapeutics Cidara Therapeutics Alector Aclaris Therapeutics Inhibikase Therapeutics TuHURA Biosciences (NASDAQ:HURA) and Spero Therapeutics (NASDAQ:SPRO) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their analyst recommendations, valuation, profitability, media sentiment, dividends, earnings, institutional ownership, community ranking and risk. Which has more risk and volatility, HURA or SPRO? TuHURA Biosciences has a beta of 0.93, indicating that its share price is 7% less volatile than the S&P 500. Comparatively, Spero Therapeutics has a beta of 0.61, indicating that its share price is 39% less volatile than the S&P 500. Is HURA or SPRO more profitable? Spero Therapeutics has a net margin of 3.30% compared to TuHURA Biosciences' net margin of 0.00%. Spero Therapeutics' return on equity of 4.03% beat TuHURA Biosciences' return on equity.Company Net Margins Return on Equity Return on Assets TuHURA BiosciencesN/A N/A -152.88% Spero Therapeutics 3.30%4.03%2.21% Does the media favor HURA or SPRO? In the previous week, TuHURA Biosciences had 3 more articles in the media than Spero Therapeutics. MarketBeat recorded 3 mentions for TuHURA Biosciences and 0 mentions for Spero Therapeutics. TuHURA Biosciences' average media sentiment score of 0.71 beat Spero Therapeutics' score of 0.00 indicating that TuHURA Biosciences is being referred to more favorably in the media. Company Overall Sentiment TuHURA Biosciences Positive Spero Therapeutics Neutral Does the MarketBeat Community believe in HURA or SPRO? Spero Therapeutics received 207 more outperform votes than TuHURA Biosciences when rated by MarketBeat users. However, 100.00% of users gave TuHURA Biosciences an outperform vote while only 69.67% of users gave Spero Therapeutics an outperform vote. CompanyUnderperformOutperformTuHURA BiosciencesOutperform Votes2100.00% Underperform VotesNo VotesSpero TherapeuticsOutperform Votes20969.67% Underperform Votes9130.33% Do insiders and institutionals have more ownership in HURA or SPRO? 0.6% of TuHURA Biosciences shares are owned by institutional investors. Comparatively, 25.6% of Spero Therapeutics shares are owned by institutional investors. 0.2% of TuHURA Biosciences shares are owned by insiders. Comparatively, 4.5% of Spero Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth. Do analysts prefer HURA or SPRO? TuHURA Biosciences currently has a consensus target price of $13.00, suggesting a potential upside of 290.39%. Spero Therapeutics has a consensus target price of $5.00, suggesting a potential upside of 501.68%. Given Spero Therapeutics' higher probable upside, analysts plainly believe Spero Therapeutics is more favorable than TuHURA Biosciences.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score TuHURA Biosciences 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 1 Strong Buy rating(s) 3.33Spero Therapeutics 0 Sell rating(s) 2 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.50 Which has higher valuation & earnings, HURA or SPRO? Spero Therapeutics has higher revenue and earnings than TuHURA Biosciences. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioTuHURA BiosciencesN/AN/A-$8.32MN/AN/ASpero Therapeutics$103.78M0.44$22.81M$0.0711.87 SummarySpero Therapeutics beats TuHURA Biosciences on 9 of the 15 factors compared between the two stocks. Get Spero Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for SPRO and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart SPRO vs. The Competition Export to ExcelMetricSpero TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$45.62M$7.07B$5.85B$9.15BDividend YieldN/A2.76%4.76%3.85%P/E Ratio11.872.5616.5114.19Price / Sales0.44304.55450.0276.60Price / Cash1.6265.6738.0134.95Price / Book0.416.717.644.63Net Income$22.81M$138.11M$3.18B$245.69M7 Day Performance1.96%-2.54%-1.95%-2.68%1 Month Performance-4.92%-2.00%-0.23%-2.16%1 Year Performance-43.47%-5.04%16.69%12.90% Spero Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)SPROSpero Therapeutics4.332 of 5 stars$0.83-0.7%$5.00+501.7%-45.0%$45.62M$103.78M11.87150HURATuHURA BiosciencesN/A$4.19-8.5%$13.00+210.3%N/A$177.15MN/A0.00N/ANews CoverageZNTLZentalis Pharmaceuticals1.9069 of 5 stars$2.43flat$8.24+239.3%-83.0%$173.16MN/A-0.98160Gap UpNLTXNeoleukin TherapeuticsN/A$18.42-1.9%N/A-41.9%$173.11MN/A-5.9290News CoverageHigh Trading VolumeCRGXCARGO Therapeutics3.094 of 5 stars$3.70+0.3%$15.00+305.4%-82.7%$170.30MN/A-0.87116Gap UpVXRTVaxart1.5405 of 5 stars$0.75-0.9%$4.00+436.0%-49.4%$169.75M$7.38M-1.82120ACRVAcrivon Therapeutics2.3269 of 5 stars$5.42+1.1%$23.67+336.7%+45.8%$168.78MN/A-2.0158Short Interest ↓CDTXCidara Therapeutics3.9216 of 5 stars$23.94+2.6%$32.20+34.5%+55.6%$168.78M$63.90M-0.9490ALECAlector4.0749 of 5 stars$1.70+1.8%$3.75+120.6%-69.9%$166.48M$97.06M-1.00270Upcoming EarningsACRSAclaris Therapeutics2.2423 of 5 stars$2.33+5.9%$11.00+372.1%+87.1%$166.43M$31.25M-4.48100Upcoming EarningsGap UpIKTInhibikase Therapeutics1.6284 of 5 stars$2.35+5.4%$6.50+176.6%+33.8%$163.00M$260,000.00-0.886 Related Companies and Tools Related Companies TuHURA Biosciences Alternatives Zentalis Pharmaceuticals Alternatives Neoleukin Therapeutics Alternatives CARGO Therapeutics Alternatives Vaxart Alternatives Acrivon Therapeutics Alternatives Cidara Therapeutics Alternatives Alector Alternatives Aclaris Therapeutics Alternatives Inhibikase Therapeutics Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:SPRO) was last updated on 2/22/2025 by MarketBeat.com Staff From Our PartnersWhat is this southern state hiding?The financial press had a field day this week after President Donald Trump and Department of Government Effici...Stansberry Research | SponsoredWhy Buffett and 100 members of Congress are Piling into this One InvestmentThis isn't just another investment. It might be the last retirement stock you'll ever need. But this win...Behind the Markets | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredBuy NVDA Now? After weeks of volatility, did President Trump just turn Nvidia (NVDA) into a raging BUY? The beloved chip...Chaikin Analytics | SponsoredThis Crypto Is Set to Explode in FebruaryIt's a groundbreaking opportunity that could be poised for extraordinary gains. The catalyst behind this su...Crypto 101 Media | SponsoredElon’s “New Gold”MIT scientists just developed a brand-new metal… A metal that’s shaping up to be, not only the biggest brea...True Market Insiders | SponsoredMarket down? Do this now.During Trump's first term, his tariffs sent gold prices soaring. Investors who acted early made a fortune. Now...Colonial Metals | SponsoredElon Takes Aim at Social SecurityElon Musk just dropped another bombshell... He revealed his DOGE organization has been taking aim at Social...Altimetry | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Spero Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Spero Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free SPRO Stock Alerts